Wolverine Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wolverine Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,800	Closed	-$3.56M	–	1658
2025 Q3	$3.56M	Buy	+7,800	New	+$3.18M	0.03%	431
2025 Q1	–	Sell	-590	Closed	-$139K	–	1558
2024 Q4	$139K	Hold	590	–	–	﹤0.01%	1073
2024 Q3	$162K	Hold	590	–	–	﹤0.01%	1047
2024 Q2	$143K	Hold	590	–	–	﹤0.01%	1044
2024 Q1	$88.2K	Buy	+590	New	+$98.4K	﹤0.01%	1070
2021 Q2	–	Sell	-406	Closed	-$57K	–	2145
2021 Q1	$57K	Buy	406 +393	+3,023%	+$59.1K	﹤0.01%	1597
2020 Q4	$1K	Buy	+13	New	+$1.74K	﹤0.01%	1591
2020 Q3	–	Sell	-13	Closed	-$1K	–	1551
2020 Q2	$1K	Buy	+13	New	+$1.75K	﹤0.01%	1487
2018 Q4	–	Sell	-12,455	Closed	-$1.09M	–	1593
2018 Q3	$1.09M	Buy	+12,455	New	+$1.25M	0.01%	772

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Wolverine Asset Management's ALNY Position: Q4 2025 in Review

Wolverine Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 7,800 shares — an estimated $3.56M sold.

Wolverine Asset Management first reported a position in ALNY in Q3 2018 and held it in 9 quarters. The position peaked at $3.56M in Q3 2025. 849 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Wolverine Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Wolverine Asset Management sold 7,800 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $3.56M.
Wolverine Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2018 and held it in 9 quarters.
Wolverine Asset Management's Alnylam Pharmaceuticals position peaked at $3.56M in Q3 2025.
849 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Wolverine Asset Management's 13F filing for Q4 2025, filed 2 Feb 2026.